ScreenerHero

KTTAPasithea Therapeutics Corp. Common Stock

NAS · US · Healthcare · Biotechnology · pasithea.com
0.5394USD+10.08%Mkt Cap: 18.02M $P/E: —

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead produc…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap18.02M $
Enterprise Value-29.96M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-20.43M $
Revenue/Share—
Last Price0.5394 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.02
PEG—
EV/EBITDA1.56
EV/Revenue—
P/S—
P/B0.32
EPS (TTM)-1.32
EPS (Forward)-0.46
52W Range
0.281015% of range2.060
52W High2.060 USD
52W Low0.2810 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-36.99%
ROA-33.91%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.21M $
CapEx (TTM)—
FCF Margin—
FCF Yield-70.10%
Net Debt-45.66M $
Net Debt/EBITDA2.39
Balance Sheet
Debt/Equity—
Current Ratio26.25
Quick Ratio24.84
Book Value/Sh1.492 USD
Cash/Share1.367 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateJan 2, 2024
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.000 USD
Upside (mean)+456.2%
Target Range3.000 USD – 3.000 USD
# Analysts1
Ownership
Shares Out.33.41M
Float21.09M
Insiders1.11%
Institutions63.23%
Short Interest
Short Ratio0.1d
Short % Float0.60%
Short % Out.0.59%
Shares Short196.60K
Short (prev mo.)287.31K
Technical
SMA 500.4976 (+8.4%)
SMA 2000.7482 (-27.9%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)286.58K
Avg Vol (10d)171.19K
Technical Indicators
RSI (14)62.1
MACD-0.0007
MACD Signal-0.0109
MACD Hist.+0.0102
BB Upper0.5190 USD
BB Middle0.4702 USD
BB Lower0.4213 USD
BB Width20.77%
ATR (14)0.0420 USD
Vol Ratio (20d)1.20x